Media headlines about Anthera Pharmaceuticals (NASDAQ:ANTH) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Anthera Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.4456775286015 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Anthera Pharmaceuticals, Inc. (ANTH) noted a price change of -1.58% and Foundation Medicine, Inc. (FMI) closes with … – Stocks Gallery (stocksgallery.com)
- Hot Stock’s Watch List: Anthera Pharmaceuticals Inc (NASDAQ: ANTH) – Alpha Beta Stock (alphabetastock.com)
- Analysts said to Hold Healthcare Stock: Anthera Pharmaceuticals, Inc. (ANTH) – Street Observer (press release) (streetobserver.com)
- Anthera Pharmaceuticals, Inc. (ANTH)- Stocks Cheering Investors with Mouthwatering Facts – NASDAQ Times (nasdaqtimes.com)
- Anthera Pharmaceuticals, Inc. (ANTH) stock RSI made a progress toward 67.70 – Voice Of Analysts (analystsbuzz.com)
Several research analysts have issued reports on ANTH shares. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Jefferies Group LLC reissued a “hold” rating and set a $1.75 price objective (down from $2.25) on shares of Anthera Pharmaceuticals in a research report on Friday, August 11th. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 25th. Finally, ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the stock. Anthera Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $5.89.
Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded down 3.51% during mid-day trading on Friday, hitting $1.65. 415,087 shares of the stock traded hands. Anthera Pharmaceuticals has a 12-month low of $0.30 and a 12-month high of $3.27. The stock’s market cap is $17.99 million. The firm’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.36.
Anthera Pharmaceuticals (NASDAQ:ANTH) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.09) by $1.12. Analysts predict that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current year.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.